Cardiff Oncology, Inc. (CRDF): Price and Financial Metrics
CRDF Price/Volume Stats
| Current price | $4.26 | 52-week high | $6.42 |
| Prev. close | $4.49 | 52-week low | $1.41 |
| Day low | $4.20 | Volume | 2,099,000 |
| Day high | $4.67 | Avg. volume | 1,215,765 |
| 50-day MA | $3.08 | Dividend yield | N/A |
| 200-day MA | $3.20 | Market Cap | 217.83M |
CRDF Stock Price Chart Interactive Chart >
Cardiff Oncology, Inc. (CRDF) Company Bio
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Price Returns
| 1-mo | 70.40% |
| 3-mo | 58.96% |
| 6-mo | 80.51% |
| 1-year | 189.80% |
| 3-year | -29.12% |
| 5-year | 222.73% |
| YTD | 187.84% |
| 2023 | 5.71% |
| 2022 | -76.71% |
| 2021 | -66.59% |
| 2020 | 1,350.81% |
| 2019 | -60.63% |
Loading social stream, please wait...